European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Freedom Finance and Binance Join Forces in Digital Assets 
MORRISTOWN, N.J., May 01, 2018 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the first quarter ended March 31, 2018, after the market close on Thursday, May 10, 2018. Pernix management will also host a conference call at 4:30pm Eastern Time to discuss the results.
| Date: | Thursday, May 10 | ||||||||
| Time: | 4:30 PM ET | ||||||||
| Toll free (U.S.): | 888-394-8218 | ||||||||
| International: | 323-701-0225 | ||||||||
| Conference ID: | 7026871 | ||||||||
| Webcast: | http://public.viavid.com/index.php?id=129150 | ||||||||
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company is currently focused on the therapeutic areas of Pain and Neurology, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its internal sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT
Investor Relations
Bob Yedid
LifeSci Advisors, LLC
[email protected]
